Heilongjiang ZBD Pharmaceutical Co Ltd Total Assets
Heilongjiang ZBD Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Heilongjiang ZBD Pharmaceutical Co Ltd (603567) holds total assets worth CN¥10.50 Billion CNY (≈ $1.54 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Heilongjiang ZBD Pharmaceutical Co Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2025)
Total assets of Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2025. This chart illustrates how Heilongjiang ZBD Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 603567 live share price for real-time trading data and today's change.
Heilongjiang ZBD Pharmaceutical Co Ltd - Asset Composition Analysis
Heilongjiang ZBD Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Heilongjiang ZBD Pharmaceutical Co Ltd total assets breakdown as of December 2025. Heilongjiang ZBD Pharmaceutical Co Ltd's total assets of CN¥10.50 Billion consist of 48.4% current assets and 51.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0.7% |
| Accounts Receivable | CN¥2.55 Billion | 24.0% |
| Inventory | CN¥1.32 Billion | 12.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.24 Billion | 11.7% |
| Goodwill | CN¥14.82 Million | 0.1% |
Asset Composition Trend (2011–2025)
This chart illustrates how Heilongjiang ZBD Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 603567 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Heilongjiang ZBD Pharmaceutical Co Ltd's current assets represent 48.4% of total assets in 2025, a decrease from 57.4% in 2011.
- Cash Position: Cash and equivalents constituted 0.7% of total assets in 2025, down from 3.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 4.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 24.0% of total assets.
Heilongjiang ZBD Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Heilongjiang ZBD Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Heilongjiang ZBD Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 2.30 | 3.10 |
| Quick Ratio | 1.03 | 1.77 | 2.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.40 Billion | CN¥4.16 Billion | CN¥3.79 Billion |
Heilongjiang ZBD Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Heilongjiang ZBD Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -16.3% |
| Total Assets | CN¥10.63 Billion |
| Market Capitalization | $689.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Heilongjiang ZBD Pharmaceutical Co Ltd's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Heilongjiang ZBD Pharmaceutical Co Ltd's assets decreased by 16.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual total assets of Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥10.63 Billion ≈ $1.56 Billion |
-16.35% |
| 2024-12-31 | CN¥12.71 Billion ≈ $1.86 Billion |
+1.98% |
| 2023-12-31 | CN¥12.47 Billion ≈ $1.82 Billion |
+6.77% |
| 2022-12-31 | CN¥11.68 Billion ≈ $1.71 Billion |
+1.47% |
| 2021-12-31 | CN¥11.51 Billion ≈ $1.68 Billion |
+12.43% |
| 2020-12-31 | CN¥10.23 Billion ≈ $1.50 Billion |
+13.48% |
| 2019-12-31 | CN¥9.02 Billion ≈ $1.32 Billion |
+10.23% |
| 2018-12-31 | CN¥8.18 Billion ≈ $1.20 Billion |
+18.82% |
| 2017-12-31 | CN¥6.89 Billion ≈ $1.01 Billion |
+7.28% |
| 2016-12-31 | CN¥6.42 Billion ≈ $939.30 Million |
+7.89% |
| 2015-12-31 | CN¥5.95 Billion ≈ $870.62 Million |
+65.08% |
| 2014-12-31 | CN¥3.60 Billion ≈ $527.39 Million |
+10.86% |
| 2013-12-31 | CN¥3.25 Billion ≈ $475.73 Million |
+52.81% |
| 2012-12-31 | CN¥2.13 Billion ≈ $311.32 Million |
+47.76% |
| 2011-12-31 | CN¥1.44 Billion ≈ $210.69 Million |
-- |
About Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the pharmaceuticals business in China. The company researches, develops, produces, and sale traditional Chinese medicine preparations, biological agents, and chemical agents, as well as involved in the pharmaceutical and Chinese medicinal materials trade; and leasing business. It also engages in pharmaceutical manufacturing; contract manufactur… Read more